Sitagliptin 50 mg + Metformin 500 mg Antidiabetics PCD Pharma Franchise

Brand Name

SITADOL-M 50/500 TABLET

Composition

Sitagliptin 50 mg & Metformin 500mg

Therapeutic Use

Management of type 2 diabetes mellitus

Size

10 x 15 Tablets

Verified Exporter

Verified Seller

Trusted Pharma

Description

SITADOL-M 50/500 Tablet contains Sitagliptin 50 mg and Metformin 500 mg, a combination of two oral antidiabetic medicines used to help manage blood glucose levels in adults with type 2 diabetes mellitus. Sitagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while metformin is a biguanide that primarily reduces glucose production by the liver and improves the body’s response to insulin.

The combination may be prescribed alongside dietary measures and physical activity when a healthcare professional determines that both medicines are appropriate. Treatment should be individualized according to blood glucose levels, kidney function, other medications and the patient’s overall health.

CardianCare is associated with cardiac and diabetic healthcare products. Pharmaceutical buyers researching a Sitagliptin 50 mg + Metformin 500 mg Tablets manufacturer India should verify the actual manufacturing company, product authorization, current availability and applicable quality documentation before procurement.
For procurement teams searching for a Sitagliptin 50 mg + Metformin 500 mg Tablets manufacturer and supplier India, relevant checks include the approved composition, dosage form, packaging, batch traceability, shelf life and verified commercial supply arrangements. CardianCare’s specific role in manufacturing or supplying this formulation requires direct confirmation.


2. Key Ingredient

Sitagliptin 50 mg + Metformin 500 mg


Composition:
– Sitagliptin – 50 mg
– Metformin – 500 mg
Sitagliptin 50 mg

Sitagliptin is a DPP-4 inhibitor. It helps prolong the activity of incretin hormones, which support glucose-dependent insulin release and help regulate glucagon secretion when blood glucose levels are elevated.Metformin 500 mg

Metformin belongs to the biguanide class of antidiabetic medicines. It primarily reduces glucose production in the liver and improves insulin sensitivity, helping the body regulate blood glucose levels.The two ingredients act through complementary mechanisms to support glycaemic control. The formulation is intended for type 2 diabetes management and is not a substitute for an individualized treatment plan.

Businesses searching for a Sitagliptin 50 mg + Metformin 500 mg pharmaceutical company India should verify the brand owner, marketing authorization holder and actual manufacturing source from reliable company and product documentation.

A Sitagliptin 50 mg + Metformin 500 mg medicine manufacturer India enquiry should include confirmation of the licensed manufacturing site, product approval, batch-release documentation and applicable regulatory requirements. These details should not be assumed from a brand name alone.


3. Key Benefits
Potential clinical benefits, when prescribed appropriately, include:
1. Complementary mechanisms: Combines a DPP-4 inhibitor with a biguanide to support blood glucose management through different pathways.
2. Glycaemic control: May help improve blood glucose control in adults with type 2 diabetes.
3. Glucose-dependent activity: Sitagliptin supports insulin release primarily when glucose levels are elevated.
4. Reduced hepatic glucose production: Metformin helps reduce the amount of glucose produced by the liver.
5. Oral treatment option: Provides an oral combination option for eligible patients when both ingredients are suitable.
6. Support for an overall care plan: Can be used alongside prescribed dietary changes, physical activity and regular blood glucose monitoring.


The degree of benefit varies by patient. The combination may not be appropriate for everyone, and metformin-related gastrointestinal effects or other safety considerations must be assessed by the prescribing clinician.

Pharmaceutical businesses researching a Sitagliptin 50 mg + Metformin 500 mg supplier India should confirm whether the specific product is currently available and request appropriate product and commercial documentation.

For a Sitagliptin 50 mg + Metformin 500 mg Tablet wholesaler and distributor India search, buyers should verify the actual seller’s licensing, product sourcing, storage practices, batch traceability and distribution authorization.

Companies seeking a Sitagliptin 50 mg + Metformin 500 mg bulk supplier India should confirm available pack sizes, minimum order quantities, stock status, delivery arrangements and shelf-life requirements directly with the authorized commercial contact.

A Sitagliptin 50 mg + Metformin 500 mg pharmaceutical distributor India enquiry should esTabletlish which entity is authorized to supply the product and whether the proposed transaction meets applicable pharmaceutical distribution requirements.


4. How Does It Work?
The two active ingredients help regulate blood glucose through different mechanisms.
Sitagliptin inhibits the DPP-4 enzyme, slowing the breakdown of incretin hormones such as GLP-1 and GIP. These hormones help increase insulin secretion in a glucose-dependent manner and reduce glucagon secretion when blood glucose is elevated.
Metformin primarily decreases glucose production by the liver and improves insulin sensitivity in peripheral tissues. It also influences glucose handling in the body.
Together, these mechanisms can help improve glycaemic control in suitable adults with type 2 diabetes. This combination does not cure diabetes, and its effectiveness depends on individual clinical factors, adherence and ongoing medical care.


5. Directions for Use

  • Dosage: Take only as prescribed by a qualified doctor. The appropriate regimen depends on the patient’s current treatment, glycaemic response, kidney function and the approved product information.
  • Administration: Follow the specific product label and pharmacist’s instructions. Metformin-containing Tablets are commonly taken with meals to help reduce gastrointestinal discomfort, but the approved directions for this formulation must be followed.
  • Regular timing: Take the medicine consistently according to the prescribed schedule.
  • Swallowing: Follow the label instructions for the dosage form. Do not crush or split the Tablet unless the product information or healthcare professional confirms that it is appropriate.
  • Kidney function: Kidney function should be assessed before and during treatment. This fixed-dose combination may be unsuitable when either ingredient requires a different dose.
  • Missed dose: Follow the instructions provided by the doctor or pharmacist. Do not double the next dose.
  • Lifestyle management: Continue the recommended diet, physical activity and blood glucose monitoring plan.

Do not start, stop or change the dosage without medical advice. Not every patient who needs one of these medicines is suitable for the fixed-dose combination.


6. Possible Side Effects

  • Possible adverse effects include:
  • Nausea or vomiting
  • Diarrhoea
  • Abdominal discomfort
  • Reduced appetite
  • Headache
  • Nasopharyngitis or upper respiratory tract symptoms


Important safety concerns include:

  • Lactic acidosis: A rare but potentially life-threatening complication associated with metformin. Warning signs may include unusual weakness, muscle pain, breathing difficulty, unusual sleepiness or severe abdominal symptoms. Seek urgent medical care if suspected.
  • Pancreatitis: Persistent, severe abdominal pain, especially if it radiates to the back, requires urgent medical assessment.
  • Hypoglycaemia: The risk may increase when the combination is used with insulin or sulfonylureas.
  • Allergic reactions: Swelling, breathing difficulty or a severe rash requires immediate medical attention.
  • Vitamin B12 deficiency: Long-term metformin treatment may reduce vitamin B12 levels in some patients.
  • Severe joint pain or blistering skin reactions: These have been reported with sitagliptin and should be discussed promptly with a healthcare professional.

This list is not exhaustive. Consult the approved prescribing information and seek medical advice about any persistent or concerning symptoms.


7. Safety Information

  • Medical supervision: Use only under the direction of a qualified healthcare professional.
  • Kidney function: Assess renal function before treatment and periodically thereafter. Metformin is contraindicated in severe renal impairment, and the combination may not be suitable when renal function requires a different sitagliptin or metformin dose.
  • Liver conditions: Inform the doctor about liver disease or other conditions that may increase the risk of lactic acidosis.
  • Acute illness and dehydration: Severe vomiting, diarrhoea, dehydration, serious infection or other acute conditions may affect treatment safety. Contact the treating clinician for instructions.
  • Surgery and contrast imaging: Tell healthcare professionals that you take metformin before surgery or investigations involving iodinated contrast. Temporary interruption may be necessary in certain circumstances.
  • Pregnancy and breastfeeding: Consult a doctor before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should review the most appropriate diabetes treatment.
  • Alcohol: Avoid excessive alcohol intake and discuss alcohol use with the prescribing clinician because it can increase the risk of metformin-associated lactic acidosis.
  • Other medicines: Inform the doctor about all prescription medicines, non-prescription products and supplements, especially other diabetes medicines.
  • Contraindications: Do not use in patients with a known serious allergy to either active ingredient or any component of the formulation. Follow the full approved product information for other contraindications.
  • Storage: Store in the original packaging according to the approved label, protected from excessive heat and moisture, and out of reach of children.
    This information is educational and does not replace approved prescribing information or individualized medical advice.


8. B2B Pharmaceutical Business Enquiries
CardianCare is associated with cardiac and diabetic healthcare products. Pharmaceutical companies, procurement teams and eligible trade partners should contact the company directly to confirm the current portfolio, the commercial role of CardianCare, product availability and any applicable distribution arrangements.

Businesses searching for a Sitagliptin 50 mg + Metformin 500 mg PCD pharma franchise India opportunity should first esTabletlish whether CardianCare currently offers such a programme. Territory rights, eligibility, product inclusion and commercial terms must be confirmed directly before publication or investment.

For a Sitagliptin 50 mg + Metformin 500 mg Tablets PCD pharma franchise enquiry, prospective partners should request written confirmation of the programme, product availability, licensing requirements and applicable promotional or commercial support.

Companies exploring a Sitagliptin 50 mg + Metformin 500 mg Tablet PCD franchise should not assume that the product or brand is included in a franchise portfolio until the company confirms this.Businesses investigating Sitagliptin 50 mg + Metformin 500 mg third party manufacturing India services must verify whether CardianCare actually provides this service. If another manufacturer is involved, the facility, authorizations, quality responsibilities and product approvals should be documented.

A Sitagliptin 50 mg + Metformin 500 mg Tablet third party manufacturer India enquiry should esTabletlish the identity of the proposed manufacturer, manufacturing-site authorization, applicable GMP status, approved specifications and batch-release arrangements.

Companies researching Sitagliptin 50 mg + Metformin 500 mg contract manufacturing India should request direct confirmation of service availability and clarify manufacturing permissions, regulatory responsibilities, technical documentation, quality agreements, batch quantities and commercial terms.

Contact CardianCare through its official company channels to request current product information and clarify available business arrangements. Manufacturing, supply, wholesale, distribution, franchise and contract-manufacturing services should be described as available only after explicit confirmation.

For more information about SITADOL-M 50/500 Tablet (Sitagliptin 50 mg + Metformin 500 mg), click here

Frequently Asked Questions

It is an oral antidiabetic combination used to help improve blood glucose control in adults with type 2 diabetes when both sitagliptin and metformin are appropriate. It should be used with the diet, exercise and monitoring plan recommended by the treating clinician.

The stated composition is Sitagliptin 50 mg and Metformin 500 mg. Sitagliptin is a DPP-4 inhibitor, while metformin is a biguanide.

Sitagliptin helps regulate glucose-dependent insulin and glucagon responses by prolonging incretin activity. Metformin primarily reduces glucose production in the liver and improves insulin sensitivity.

The combination offers complementary mechanisms for glycaemic control and an oral treatment option for eligible adults. Individual benefits depend on the patient's condition, prescribed regimen and response to treatment.

Take it exactly as prescribed and follow the approved product label. Metformin-containing medicines are commonly taken with meals to reduce stomach discomfort, but the directions for the specific formulation should be confirmed.

Possible effects include nausea, diarrhoea, abdominal discomfort, reduced appetite and headache. Serious warning signs, including severe abdominal pain, unusual breathing difficulty or a severe allergic reaction, require prompt medical assessment.

Patients with kidney impairment, liver disease, a history of pancreatitis, dehydration or other serious medical conditions should discuss suitability with their doctor. The combination may not be appropriate if either ingredient requires a different dose.

It may be prescribed alongside selected treatments under medical supervision. Combining it with insulin or sulfonylureas may increase the risk of hypoglycaemia, so the clinician may need to review the overall regimen.

Buyers should confirm the approved composition, strength, dosage form, product authorization, actual manufacturing source, batch documentation, shelf life, packaging, storage conditions and seller's authorization. Current stock and commercial terms should also be confirmed.

These services should not be assumed. Contact CardianCare directly to confirm its role in the product, current availability and whether any supplier, distributor, franchise, third-party manufacturing or contract-manufacturing arrangement is actually offered.

Reviews

There are no reviews yet.

Be the first to review “Sitagliptin 50 mg + Metformin 500 mg Antidiabetics PCD Pharma Franchise”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line